Britian has jumped the gun on gene editing
By Donna Dickenson,
Telegraph [UK]
| 02. 02. 2016
Untitled Document
For the first time Britain’s Human Fertilisation and Embryology Authority (HFEA) has granted researchers permission to use a new “gene editing” technique called Crispr/Cas9 to modify human embryos. This is despite a global summit held last December by the National Academies of Science in Washington which warned that, when it comes to this powerful new technique, no nation should go it alone. Other countries such as the United States are just as advanced as Britain in gene editing – indeed, the techniques authorised by HFEA were partly developed in America. But these nations are, rightly, being more cautious in using it.
Why? Their objections do not rest on religion or Luddite opposition to new technology. And it is not gene editing per se – they have fewer concerns about the technique’s use to correct genetic problems in individual living patients. But around the world, expert scientists and bioethicists are worried about its use to modify human embryos. If such embryos are reimplanted in the womb and born, genetic modifications would not be confined to them, but passed down...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Briana Contreras, Managed Healthcare Executive | 06.17.2025